BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bhathena J, Martoni C, Kulamarva A, Tomaro-Duchesneau C, Malhotra M, Paul A, Urbanska AM, Prakash S. Oral probiotic microcapsule formulation ameliorates non-alcoholic fatty liver disease in Bio F1B Golden Syrian hamsters. PLoS One. 2013;8:e58394. [PMID: 23554890 DOI: 10.1371/journal.pone.0058394] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 de Castro CA, dos Santos Dias MM, da Silva KA, dos Reis SA, da Conceição LL, De Nadai Marcon L, de Sousa Moraes LF, do Carmo Gouveia Peluzio M. Liver Biomarkers and Their Applications to Nutritional Interventions in Animal Studies. In: Patel VB, Preedy VR, editors. Biomarkers in Liver Disease. Dordrecht: Springer Netherlands; 2017. pp. 129-52. [DOI: 10.1007/978-94-007-7675-3_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
2 Rezazadeh L, Gargari BP, Jafarabadi MA, Alipour B. Effects of probiotic yogurt on glycemic indexes and endothelial dysfunction markers in patients with metabolic syndrome. Nutrition 2019;62:162-8. [DOI: 10.1016/j.nut.2018.12.011] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 9.7] [Reference Citation Analysis]
3 Minj J, Chandra P, Paul C, Sharma RK. Bio-functional properties of probiotic Lactobacillus: current applications and research perspectives. Crit Rev Food Sci Nutr 2021;61:2207-24. [PMID: 32519883 DOI: 10.1080/10408398.2020.1774496] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Nabavi S, Rafraf M, Somi MH, Homayouni-Rad A, Asghari-Jafarabadi M. Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease. J Dairy Sci 2014;97:7386-93. [PMID: 25306266 DOI: 10.3168/jds.2014-8500] [Cited by in Crossref: 99] [Cited by in F6Publishing: 89] [Article Influence: 12.4] [Reference Citation Analysis]
5 Machado MV, Cortez-Pinto H. Diet, Microbiota, Obesity, and NAFLD: A Dangerous Quartet. Int J Mol Sci. 2016;17:481. [PMID: 27043550 DOI: 10.3390/ijms17040481] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 8.8] [Reference Citation Analysis]
6 Berkes E, Liao YH, Neef D, Grandalski M, Monsul N. Potentiated In Vitro Probiotic Activities of Lactobacillus fermentum LfQi6 Biofilm Biomass Versus Planktonic Culture. Probiotics Antimicrob Proteins 2020;12:1097-114. [PMID: 31828607 DOI: 10.1007/s12602-019-09624-8] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
7 Tomaro-Duchesneau C, Saha S, Malhotra M, Jones ML, Rodes L, Prakash S. Lactobacillus fermentum NCIMB 5221 and NCIMB 2797 as cholesterol-lowering probiotic biotherapeutics: in vitro analysis. Benef Microbes 2015;6:861-9. [PMID: 26322545 DOI: 10.3920/BM2015.0021] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
8 Sepideh A, Karim P, Hossein A, Leila R, Hamdollah M, Mohammad E G, Mojtaba S, Mohammad S, Ghader G, Seyed Moayed A. Effects of Multistrain Probiotic Supplementation on Glycemic and Inflammatory Indices in Patients with Nonalcoholic Fatty Liver Disease: A Double-Blind Randomized Clinical Trial. J Am Coll Nutr 2016;35:500-5. [PMID: 26430826 DOI: 10.1080/07315724.2015.1031355] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.9] [Reference Citation Analysis]
9 Feng RN, Du SS, Wang C, Li YC, Liu LY, Guo FC, Sun CH. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population. World J Gastroenterol 2014; 20(47): 17932-17940 [PMID: 25548491 DOI: 10.3748/wjg.v20.i47.17932] [Cited by in CrossRef: 103] [Cited by in F6Publishing: 92] [Article Influence: 12.9] [Reference Citation Analysis]
10 Gao X, Zhu Y, Wen Y, Liu G, Wan C. Efficacy of probiotics in non-alcoholic fatty liver disease in adult and children: A meta-analysis of randomized controlled trials. Hepatol Res 2016;46:1226-33. [PMID: 26866817 DOI: 10.1111/hepr.12671] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 7.5] [Reference Citation Analysis]
11 Arguello G, Balboa E, Arrese M, Zanlungo S. Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2015;1852:1765-78. [DOI: 10.1016/j.bbadis.2015.05.015] [Cited by in Crossref: 127] [Cited by in F6Publishing: 134] [Article Influence: 18.1] [Reference Citation Analysis]
12 Tomaro-Duchesneau C, Saha S, Malhotra M, Jones ML, Labbé A, Rodes L, Kahouli I, Prakash S. Effect of orally administered L. fermentum NCIMB 5221 on markers of metabolic syndrome: an in vivo analysis using ZDF rats. Appl Microbiol Biotechnol. 2014;98:115-126. [PMID: 24121931 DOI: 10.1007/s00253-013-5252-8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
13 Kondratiuk VE, Tarasenko OM, Karmazina OM, Taranchuk VV. Impact of the Synbiotics and Urate-Lowering Therapy on Gut Microbiota and Cytokine Profile in Patients with Chronic Gouty Arthritis. J Med Life 2020;13:490-8. [PMID: 33456597 DOI: 10.25122/jml-2020-0065] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Asgharian A, Askari G, Esmailzade A, Feizi A, Mohammadi V. The Effect of Symbiotic Supplementation on Liver Enzymes, C-reactive Protein and Ultrasound Findings in Patients with Non-alcoholic Fatty Liver Disease: A Clinical Trial. Int J Prev Med 2016;7:59. [PMID: 27076897 DOI: 10.4103/2008-7802.178533] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 5.5] [Reference Citation Analysis]
15 S Lavekar A, V Raje D, Manohar T, A Lavekar A. Role of Probiotics in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-analysis. Euroasian J Hepatogastroenterol 2017;7:130-7. [PMID: 29201794 DOI: 10.5005/jp-journals-10018-1233] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
16 Saha S, Tomaro-Duchesneau C, Rodes L, Malhotra M, Tabrizian M, Prakash S. Investigation of probiotic bacteria as dental caries and periodontal disease biotherapeutics. Benef Microbes 2014;5:447-60. [PMID: 25006013 DOI: 10.3920/BM2014.0011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
17 Paolella G, Mandato C, Pierri L, Poeta M, Di Stasi M, Vajro P. Gut-liver axis and probiotics: Their role in non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(42): 15518-15531 [PMID: 25400436 DOI: 10.3748/wjg.v20.i42.15518] [Cited by in CrossRef: 88] [Cited by in F6Publishing: 85] [Article Influence: 11.0] [Reference Citation Analysis]
18 Huang Y, Gao L. Role of intestinal microorganisms in brain-gut axis and related diseases. Shijie Huaren Xiaohua Zazhi 2017; 25(34): 3032-3037 [DOI: 10.11569/wcjd.v25.i34.3032] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
19 Russo M, Marquez A, Herrera H, Abeijon-mukdsi C, Saavedra L, Hebert E, Gauffin-cano P, Medina R. Oral administration of Lactobacillus fermentum CRL1446 improves biomarkers of metabolic syndrome in mice fed a high-fat diet supplemented with wheat bran. Food Funct 2020;11:3879-94. [DOI: 10.1039/d0fo00730g] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
20 Jeon MG, Kim TR, Lee JY, Kim HS, Ji Y, Holzapfel WH, Bae D, Choi CY, Hwang YP. Hepatoprotective Effects of Streptococcus thermophilus LM1012 in Mice Exposed to Air Pollutants. J Med Food 2020;23:852-61. [PMID: 32513044 DOI: 10.1089/jmf.2019.4636] [Reference Citation Analysis]
21 Paulino do Nascimento LC, Lacerda DC, Ferreira DJS, de Souza EL, de Brito Alves JL. Limosilactobacillus fermentum, Current Evidence on the Antioxidant Properties and Opportunities to be Exploited as a Probiotic Microorganism. Probiotics Antimicrob Proteins 2022. [PMID: 35467236 DOI: 10.1007/s12602-022-09943-3] [Reference Citation Analysis]
22 Vassalle C, Mazzone A, Sabatino L, Carpeggiani C. Uric Acid for Cardiovascular Risk: Dr. Jekyll or Mr. Hide? Diseases 2016;4:E12. [PMID: 28933392 DOI: 10.3390/diseases4010012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
23 Green M, Arora K, Prakash S. Microbial Medicine: Prebiotic and Probiotic Functional Foods to Target Obesity and Metabolic Syndrome. Int J Mol Sci 2020;21:E2890. [PMID: 32326175 DOI: 10.3390/ijms21082890] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
24 Iqbal UH, Westfall S, Prakash S. Novel microencapsulated probiotic blend for use in metabolic syndrome: design and in-vivo analysis. Artif Cells Nanomed Biotechnol 2018;46:S116-24. [PMID: 30033770 DOI: 10.1080/21691401.2018.1489270] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
25 Asgharian A, Mohammadi V, Gholi Z, Esmaillzade A, Feizi A, Askari G. The Effect of Synbiotic Supplementation on Body Composition and Lipid Profile in Patients with NAFLD: A Randomized, Double Blind, Placebo-Controlled Clinical Trial Study. Iran Red Crescent Med J 2017;19. [DOI: 10.5812/ircmj.42902] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
26 Saha S, Tomaro-Duchesneau C, Daoud JT, Tabrizian M, Prakash S. Novel probiotic dissolvable carboxymethyl cellulose films as oral health biotherapeutics: in vitro preparation and characterization. Expert Opin Drug Deliv 2013;10:1471-82. [PMID: 23713443 DOI: 10.1517/17425247.2013.799135] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]